


Amendments to the Claims:

This listing of claims will replace all prior versions, and listings of claims in the application:

Listing of Claims:

Claims 1-38 (cancelled).

Claim 39 (new): A compound having the formula:



wherein

A is Cl or CF₃;

C is Cl or CF₃;

D is H or CH₃;

V is F or Cl;

X is a member selected from the group consisting of H, CH₃, COOH, and CO₂CH₃; and

Y is a member selected from the group consisting of H, CO₂H and CO₂CH₃;

or a pharmaceutically acceptable salt thereof.

Claim 40 (new): The compound of claim 39, wherein V is Cl.

Claim 41 (new): The compound of claim 39, wherein X and Y are each H.

Claim 42 (new): The compound of claim 39, wherein A is Cl.

Claim 43 (new): The compound of claim 39, wherein A is CF₃.

Claim 44 (new): The compound of claim 39, wherein D is H.

Claim 45 (new): The compound of claim 39, wherein A is Cl and D is H.


Claim 46 (new): The compound of claim 39, wherein A is Cl; C is Cl; and V is Cl.

Claim 47 (new): The compound of claim 39, wherein C is CF₃.

Claim 48 (new): The compound of claim 39, wherein A is Cl; C is Cl; V is Cl, D is CH₃, and X and Y are each H.

Claim 49 (new): The compound of claim 39, wherein A is Cl; C is Cl; V is Cl, D is H, and X and Y are each H.

Claim 50 (new): A composition comprising a pharmaceutically acceptable carrier or excipient and a compound having the formula:



wherein

A is Cl or CF₃;

C is Cl or CF₃;

D is H or CH₃;

V is F or Cl;

X is a member selected from the group consisting of H, CH₃, COOH, and CO₂CH₃; and

Y is a member selected from the group consisting of H, CO₂H and CO₂CH₃;

or a pharmaceutically acceptable salt thereof.

Claim 51 (new): The composition of claim 50, wherein V is Cl.

Claim 52 (new): The composition of claim 50, wherein X and Y are each H.

Claim 53 (new): The composition of claim 50, wherein A is Cl.

Claim 54 (new): The composition of claim 50, wherein A is CF₃.

Claim 55 (new): The composition of claim 50, wherein D is H.

Claim 56 (new): The composition of claim 50, wherein A is Cl and D is H.


Claim 57 (new): The composition of claim 50, wherein A is Cl; C is Cl; and V is Cl.

Claim 58 (new): The composition of claim 50, wherein C is CF₃.

Claim 59 (new): The composition of claim 50, wherein A is Cl; C is Cl; V is Cl, D is CH₃, and X and Y are each H.

Claim 60 (new): The composition of claim 50, wherein A is Cl; C is Cl; V is Cl, D is H, and X and Y are each H.

Claim 61 (new): A method for treating or preventing a metabolic disorder or an inflammatory condition, comprising administering to a subject in need thereof a therapeutically effective amount of a compound having the formula:



wherein

A is Cl or CF₃;

C is Cl or CF₃;

D is H or CH₃;

V is F or Cl;

X is a member selected from the group consisting of H, CH₃, COOH, and CO₂CH₃; and

Y is a member selected from the group consisting of H, CO₂H and CO₂CH₃;

or a pharmaceutically acceptable salt thereof.

Claim 62 (new): The method of claim 61, wherein A is Cl; C is Cl; D is H; V is Cl; and X and Y are each H.

Claim 63 (new): The method of claim 61, wherein said subject is a human.

Claim 64 (new): The method of claim 61, wherein said administering is oral.

Claim 65 (new): The method of 61, wherein said administering is parenteral.

Claim 66 (new): The method of claim 61, wherein said administering is topical.


Claim 67 (new): The method of claim 61, wherein said metabolic disorder is selected from the group consisting of non-insulin dependent diabetes mellitus, obesity, hypercholesterolemia, hyperlipidemia, dyslipidemia, hypertriglyceridemia, hyperglycemia, insulin resistance and hyperinsulinemia.

Claim 68 (new): The method of claim 61, wherein said inflammatory condition is selected from the group consisting of rheumatoid arthritis and atherosclerosis.

Claim 69 (new): The method of claim 61, wherein said metabolic disorder or inflammatory condition is mediated by PPAR γ .

Claim 70 (new): The method of claim 61, wherein the metabolic disorder is non-insulin dependent diabetes mellitus.

Claim 71 (new): A method for treating or preventing a condition or disorder mediated by PPAR γ , comprising administering to a subject in need thereof a therapeutically effective amount of a compound having the formula:



wherein

A is Cl or CF₃;

C is Cl or CF₃;

D is H or CH₃;

V is F or Cl;

X is a member selected from the group consisting of H, CH₃, COOH, and CO₂CH₃; and

Y is a member selected from the group consisting of H, CO₂H and CO₂CH₃;

or a pharmaceutically acceptable salt thereof.

Claim 72 (new): The method of claim 71, wherein A is Cl; C is Cl; D is H; V is Cl; and X and Y are each H.

Claim 73 (new): The method of claim 71, wherein said subject is a human.

Claim 74 (new): The method of claim 71, wherein said administering is oral.

Claim 75 (new): The method of claim 71, wherein said administering is parenteral.


Claim 76 (new): The method of claim 71, wherein said administering is topical.

Claim 77 (new): The method of claim 71, wherein said condition or disorder is a metabolic disorder or an inflammatory condition.

Claim 78 (new): The method of claim 71, wherein said metabolic disorder is selected from the group consisting of non-insulin dependent diabetes mellitus, obesity, hypercholesterolemia, hyperlipidemia, dyslipidemia, hypertriglyceridemia, hyperglycemia, insulin resistance and hyperinsulinemia.

Claim 79 (new): The method of claim 71, wherein said inflammatory condition is selected from the group consisting of rheumatoid arthritis and atherosclerosis.

Claim 80 (new): A method for modulating PPAR γ , comprising contacting a cell with a compound having the formula:



wherein

A is Cl or CF₃;

C is Cl or CF₃;

D is H or CH₃;

V is F or Cl;

X is a member selected from the group consisting of H, CH₃, COOH, and
CO₂CH₃; and

Y is a member selected from the group consisting of H, CO₂H and
CO₂CH₃;

or a pharmaceutically acceptable salt thereof.

Claim 81 (new): The method in accordance with claim 80, wherein A is Cl; C is Cl; D is H; V is Cl; and X and Y are each H.

Claim 82 (new): The method of claim 80, wherein said compound is a PPAR γ antagonist.

Claim 83 (new): The method of Claim 80, wherein said compound is PPAR γ agonist.